BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
nitric oxide metabolic process
,
Influenza
,
Adipose tissue
,
DNA fingerprint
,
IGF1
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
pf 03814735
(compound)
Summary
General Info
Genetic Markers
Most Correlated Genes
LPL
CRIP1
HBB
XIST
COL11A1
Explore Genetic Markers Results
Pathway Enrichment
Most Correlated Biogroups
regulation of nitrogen compound metabolic process
organic cyclic compound binding
heterocyclic compound binding
cell periphery
cytosol
Explore Pathway Enrichment Results
Curated Studies
Most Correlated Studies
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (1 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (2 of 4)
L1000 CMAP - Breast cancer MCF7 cells treated with small molecule perturbagens (3 of 4)
Explore Curated Studies Results
Literature
Most Relevant Literature
An integrated genomic approach to identify predictive biomarkers of response to the aurora kinase in…
PF-03814735, an orally bioavailable small molecule aurora kinase inhibitor for cancer therapy.
Phase I, open-label, multicentre, dose-escalation, pharmacokinetic and pharmacodynamic trial of the …
Phenotypic Screening for Small Molecules that Protect β-Cells from Glucolipotoxicity.
Inhibitors of One or More Cellular Aurora Kinases Impair the Replication of Herpes Simplex Virus 1 a…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ